Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PGNY 
Progyny Inc (PGNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: PGNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $28.25
1 Year Target Price $28.25
| 4 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.67% | Avg. Invested days 38 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94B USD | Price to earnings Ratio 38.15 | 1Y Target Price 28.25 |
Price to earnings Ratio 38.15 | 1Y Target Price 28.25 | ||
Volume (30-day avg) 10 | Beta 1.33 | 52 Weeks Range 13.39 - 26.76 | Updated Date 09/15/2025 |
52 Weeks Range 13.39 - 26.76 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.28% | Operating Margin (TTM) 7.32% |
Management Effectiveness
Return on Assets (TTM) 6.57% | Return on Equity (TTM) 10.94% |
Valuation
Trailing PE 38.15 | Forward PE 11.43 | Enterprise Value 1655877026 | Price to Sales(TTM) 1.56 |
Enterprise Value 1655877026 | Price to Sales(TTM) 1.56 | ||
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA 20.5 | Shares Outstanding 85982400 | Shares Floating 79593056 |
Shares Outstanding 85982400 | Shares Floating 79593056 | ||
Percent Insiders 7.58 | Percent Institutions 103.87 |
Upturn AI SWOT
Progyny Inc
Company Overview
History and Background
Progyny Inc. was founded in 2008 and went public in 2019. It focuses on providing comprehensive fertility and family building benefits solutions to employers.
Core Business Areas
- Fertility Benefit Management: Progyny manages fertility benefits programs for employers, offering access to a network of fertility specialists and comprehensive treatment coverage.
Leadership and Structure
Progyny is led by CEO Pete Anevski. The organizational structure includes departments such as sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Progyny Rx: A pharmacy benefits management solution specifically tailored for fertility medications. Competitors include traditional PBMs and specialty pharmacies. Market Share Data is not publicly available.
- Progyny Fertility Benefit: The core fertility benefits program includes access to high-quality fertility care, SMART Cycle approach (a bundled, comprehensive approach to fertility treatment), and patient care advocates. Competitors include WINFertility, Carrot Fertility, and other health insurance providers offering fertility benefits. Market Share Data is not publicly available.
Market Dynamics
Industry Overview
The fertility benefits market is growing due to increasing awareness, rising infertility rates, and employer demand for inclusive benefits packages.
Positioning
Progyny is a leading provider of fertility benefits, known for its high success rates and focus on quality care. Their competitive advantage lies in their comprehensive approach and network of top-tier clinics.
Total Addressable Market (TAM)
The TAM for fertility benefits is estimated to be in the billions of dollars, growing annually. Progyny is well-positioned to capture a significant share of this market due to its established reputation and comprehensive offerings.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Comprehensive fertility benefits solution
- High success rates
- Extensive network of fertility specialists
- Dedicated patient care advocates
Weaknesses
- High cost of services
- Dependence on employer-sponsored benefits
- Potential for adverse selection (higher utilization by employees)
- Scalability challenges in managing complex care
Opportunities
- Expanding into new geographic markets
- Offering additional family-building benefits (e.g., adoption, surrogacy)
- Partnering with health systems and payers
- Developing new technologies to improve fertility care
Threats
- Increased competition from other fertility benefits providers
- Changes in healthcare regulations
- Economic downturn impacting employer benefits spending
- Advances in fertility treatments reducing demand for traditional IVF
Competitors and Market Share
Key Competitors
- WINFertility
- Carrot Fertility
- Teladoc Health (TDOC)
Competitive Landscape
Progyny's advantages include its comprehensive approach, high success rates, and strong brand. Disadvantages may include higher costs compared to some competitors.
Growth Trajectory and Initiatives
Historical Growth: Progyny has experienced significant revenue growth in recent years driven by increased adoption of its fertility benefits programs.
Future Projections: Analysts project continued revenue growth for Progyny based on market trends and company initiatives. However, exact numbers are dependent on market conditions.
Recent Initiatives: Recent initiatives include expanding their network, offering new family-building benefits, and investing in technology to improve the patient experience.
Summary
Progyny is a strong player in the fertility benefits market, driven by its comprehensive solution and focus on quality care. Its financial growth has been notable, but competition is increasing. Progyny needs to continue to innovate and expand its offerings to maintain its leading position and watch out for economic downturns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is based on limited publicly available information and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Progyny Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-10-25 | CEO & Director Mr. Peter Anevski CPA | ||
Sector Healthcare | Industry Healthcare Plans | Full time employees 675 | Website https://www.progyny.com |
Full time employees 675 | Website https://www.progyny.com | ||
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.